A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (NCT04658862)

🧪 Interventions in This Study

• Cetrelimab (BIOLOGICAL)
• TAR-200 (DRUG)
• Cisplatin (DRUG)
• Gemcitabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (290 Sites)

Showing the first 25 of 290 sites.

• Loma Linda Univ Faculty Medic — Loma Linda, California
• University of Southern California — Los Angeles, California
• Providence Saint John s Health Center — Santa Monica, California
• Stanford University Medical Center — Stanford, California
• The Urology Center of Colorado — Denver, Colorado
• Foothills Urology - Golden Off — Golden, Colorado
• Boca Raton Regional Hospital — Boca Raton, Florida
• Urological Research Network — Hialeah, Florida
• Memorial Healthcare System — Pembroke Pines, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• DuPage Medical Group — Lisle, Illinois
• University Hospitals Seidman Cancer Center — Ann Arbor, Michigan
• Michigan Institute of Urology — Troy, Michigan
• Adult Pediatric Urology & Urogynecology, P.C — Omaha, Nebraska
• Garden State Urology — Morristown, New Jersey
• New Jersey Urology LLC — Voorhees Township, New Jersey
• Cardiology Clinic at Montefiore Hutchinson Complex — The Bronx, New York
• Duke University Medical Center — Durham, North Carolina
• Vidant Urology - Greenville — Greenville, North Carolina
• Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center — Winston-Salem, North Carolina
• Wexner Medical Center at the Ohio State University — Columbus, Ohio
• Stephenson Cancer Center — Oklahoma City, Oklahoma
• MidLantic Urology — Bala-Cynwyd, Pennsylvania
• Carolina Urologic Research Center — Myrtle Beach, South Carolina
• University of Tennessee Medical Center — Knoxville, Tennessee

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urinary Bladder Neoplasms

• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer — Tucson, Arizona
• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) — Birmingham, Alabama
• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) — Washington D.C., District of Columbia
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Tucson, Arizona
• A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) — Bakersfield, California

Explore by condition: All Urinary Bladder Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.